Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1063MR)

This product GTTS-WQ1063MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF10B gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_003842.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 8795
UniProt ID O14763
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ1063MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4020MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI 655066
GTTS-WQ1230MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABR-217620
GTTS-WQ8603MR IVTScrip™ mRNA-Anti-CD33, HuM195(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuM195
GTTS-WQ2679MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG 785
GTTS-WQ905MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ8678MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ1307MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ8385MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA aTROP2S7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW